These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 27539372

  • 1. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
    Flora DR, Rettie AE, Brundage RC, Tracy TS.
    J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
    [Abstract] [Full Text] [Related]

  • 2. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [Abstract] [Full Text] [Related]

  • 3. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H, Echizen H.
    Clin Pharmacokinet; 2001 Mar; 40(8):587-603. PubMed ID: 11523725
    [Abstract] [Full Text] [Related]

  • 4. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H.
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [Abstract] [Full Text] [Related]

  • 5. Relationship of S/R warfarin ratio with CYP2C9 genotypes in Pakistani population.
    Qayyum A, Najmi MH, Raza SI, Rajput TA, Naveed AK.
    Pak J Pharm Sci; 2019 Jul; 32(4):1581-1588. PubMed ID: 31608877
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
    Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG.
    Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
    [Abstract] [Full Text] [Related]

  • 7. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H.
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [Abstract] [Full Text] [Related]

  • 8. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J, Tian L, Huang J, Huang S, Chai T, Shen J.
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [Abstract] [Full Text] [Related]

  • 9. Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin.
    Pavani A, Naushad SM, Stanley BA, Kamakshi RG, Abinaya K, Amaresh Rao M, Uma A, Kutala VK.
    Pharmacogenomics; 2015 Feb; 16(4):393-400. PubMed ID: 25823787
    [Abstract] [Full Text] [Related]

  • 10. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.
    Shaul C, Blotnick S, Adar L, Muszkat M, Bialer M, Caraco Y.
    Clin Pharmacokinet; 2022 Aug; 61(8):1187-1198. PubMed ID: 35699912
    [Abstract] [Full Text] [Related]

  • 11. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.
    Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y.
    Mol Diagn Ther; 2017 Feb; 21(1):75-83. PubMed ID: 27878474
    [Abstract] [Full Text] [Related]

  • 12. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D.
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [Abstract] [Full Text] [Related]

  • 13. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
    Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS.
    J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
    [Abstract] [Full Text] [Related]

  • 14. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R.
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [Abstract] [Full Text] [Related]

  • 15. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E, Stefanović M, Samardzija M.
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [Abstract] [Full Text] [Related]

  • 16. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.
    Bryk A, Wypasek E, Awsiuk M, Maj D, Undas A.
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):257-64. PubMed ID: 25986145
    [Abstract] [Full Text] [Related]

  • 17. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
    Chang AT, Bertino JS, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD.
    Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
    [Abstract] [Full Text] [Related]

  • 18. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
    Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP.
    Chem Res Toxicol; 2010 May 17; 23(5):939-45. PubMed ID: 20429590
    [Abstract] [Full Text] [Related]

  • 19. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
    Thijssen HH, Ritzen B.
    Clin Pharmacol Ther; 2003 Jul 17; 74(1):61-8. PubMed ID: 12844136
    [Abstract] [Full Text] [Related]

  • 20. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS.
    J Clin Pharmacol; 2001 Jul 17; 41(7):715-22. PubMed ID: 11452703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.